Zovirax Shortage: What Providers and Prescribers Need to Know in 2026

As a healthcare provider, you have likely seen the downstream effects of acyclovir supply disruptions firsthand: patients calling for emergency refills, pharmacies unable to fill standing prescriptions, and clinical uncertainty about when supply will fully normalize. This briefing gives you the clinical and logistical information needed to navigate the 2026 Zovirax landscape and ensure continuity of care for your patients.

Current Supply Status (as of Mid-2026)

The supply environment for acyclovir in 2026 is best described as stable but fragile, with significant differences by formulation:

Oral acyclovir (tablets, capsules, suspension): Generally available through major distributors. Individual retail pharmacy stockouts continue due to allocation limits and demand spikes. Rural and underserved pharmacies face disproportionate access challenges.

IV acyclovir sodium injection: Active intermittent shortage. ASHP continues to list acyclovir injection on its official drug shortage database. As of April 2026, Slate Run Pharma's 10 mL vials are on backorder with no estimated release date. Fresenius Kabi's 20 mL vials returned to availability by late 2024.

Topical acyclovir: Generally available. Brand Zovirax cream is expensive ($400+ without insurance); generic is widely available and much more affordable.

Shortage Timeline and Root Causes

Acyclovir injection shortages began in 2020, driven by manufacturing constraints and increased demand partly attributable to pandemic-era supply chain disruptions. The shortage persisted through 2022–2023, during which some hospitals rationed IV acyclovir or converted patients to high-dose oral valacyclovir when clinically appropriate. Recovery began in 2024 with manufacturer production increases.

The root causes of the persistent shortage are structural: low list prices on generic injectables reduce manufacturer investment in capacity, and generic manufacturer consolidation means that a single disruption at one facility can destabilize supply nationally. This pattern, documented in peer-reviewed literature as a systemic issue across antimicrobial classes, is unlikely to resolve without policy intervention or market structure changes.

Prescribing Implications by Indication

Outpatient HSV and VZV management:

For outpatient management of herpes simplex and varicella-zoster infections, oral acyclovir remains first-line and is generally available. When acyclovir is unavailable, valacyclovir is the preferred substitute for all outpatient indications due to its superior oral bioavailability (3–5x that of acyclovir):

Genital herpes suppression: Acyclovir 400 mg BID → Valacyclovir 500 mg QD (or 1g QD for ≥10 recurrences/year)

Genital herpes, episodic: Acyclovir 200 mg 5x/day × 5 days → Valacyclovir 500 mg BID × 3 days

Herpes zoster: Acyclovir 800 mg 5x/day × 7–10 days → Valacyclovir 1g TID × 7 days (or Famciclovir 500 mg TID × 7 days)

Varicella (chickenpox): Acyclovir 20 mg/kg (max 800 mg) QID × 5 days is preferred for pediatric patients. Valacyclovir is an alternative in adults.

IV acyclovir indications with no equivalent oral substitute:

For HSV encephalitis, neonatal herpes, and severe VZV in immunocompromised patients, IV acyclovir remains the standard of care with no true equivalent substitute. If IV acyclovir is unavailable:

Contact hospital pharmacy for alternative sourcing or compounding options

For less severe cases, high-dose oral valacyclovir (1g TID) may provide adequate bioavailability, though this is off-label for most IV indications

Foscarnet is an alternative for acyclovir-resistant HSV, but carries significant nephrotoxicity risk and requires close monitoring

Counseling Patients on Access and Cost

Even when oral acyclovir is available, cost can be a barrier for uninsured or underinsured patients. Key pricing data for 2026:

Generic acyclovir 400 mg (60 tablets): $70–$105 cash price at retail; $8–$15 with discount cards (SingleCare, GoodRx)

Generic valacyclovir 500 mg (30 tablets): $10–$25 with discount cards

Generic famciclovir 500 mg (21 tablets): $15–$40 with discount cards

For patients who are uninsured or facing financial hardship, direct them to NeedyMeds (needymeds.org), RxAssist (rxassist.org), Walmart's $4 prescription program (which covers some acyclovir formulations), and Cost Plus Drugs (costplusdrugs.com) for near-wholesale generic pricing with home delivery.

38,781+ patients found their medications in stock

38K+

Find Zovirax In Stock Today →

Helping Patients Find Their Medication

When patients can't find acyclovir at their usual pharmacy, direct them to medfinder. medfinder calls pharmacies near the patient to identify which ones have the medication in stock and texts results directly to the patient. This is particularly valuable for patients who lack transportation flexibility or are managing complex medication regimens.

Prescribing Tips to Reduce Access Friction

Write 90-day prescriptions for suppressive therapy patients to reduce refill frequency and exposure to spot shortages

Pre-authorize valacyclovir as a therapeutic equivalent on prescriptions ("may substitute valacyclovir") so pharmacists can switch without requiring a new prescription

Consider mail-order pharmacy referrals for patients on long-term maintenance therapy

For rural patients, specifically direct to independent pharmacies or warehouse club pharmacies (Costco) which may stock more reliably than urban chains

Skip the calls, skip the stress.

Find Zovirax In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Summary for Clinical Practice

The 2026 acyclovir supply situation requires providers to be proactive: prescribe 90-day supplies when appropriate, be ready to substitute valacyclovir for outpatient indications, and direct patients to medfinder and discount card programs when access is a barrier. See our full provider's guide to helping patients find Zovirax for additional resources.